Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is positioned favorably within the biopharmaceutical market due to its innovative portfolio targeting neurodegenerative diseases, particularly through its development of therapeutic and diagnostic products aimed at misfolded proteins. The anticipated results from the upcoming EVOKE trial and promising data from the ACI-7104.056 program, which has shown a significant increase in antibodies against pathogenic variants, highlight the potential for strong clinical efficacy and safety in treatments. Additionally, the company's focus on timely patient identification and easy-to-administer maintenance therapies aligns with market needs, reinforcing a positive outlook for the company's future growth and potential success in the Alzheimer's disease treatment landscape.

Bears say

AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, indicating ongoing financial challenges as the company continues to advance its clinical trials. For the 2025 fiscal year, the net loss expanded to CHF 70.4 million, accompanied by a basic and diluted earnings per share (EPS) of (0.70), further reflecting the company's struggles to achieve profitability. Additionally, AC Immune faces multiple industry-specific risks, such as unpredictable clinical outcomes, regulatory hurdles, and the complexities of entering an evolving and price-sensitive market for neurodegenerative disease treatments.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.